Heparin-Induced Thrombocytopenia Score Card Study
Main Research Question:
Can two new types of test, one called the 4T's score and the other called a rapid assay, help doctors correctly identify which patients are unlikely to have heparin-induced thrombocytopenia (HIT)?
HIT is a severe allergic reaction to the blood thinner heparin. This allergic reaction can lead to heart attacks, strokes, limb amputations, and death. Because heparin is one of the most commonly used drugs in the hospital setting, it is very important that the investigators are able to correctly identify who can safely continue to take heparin and who cannot.
It can be very difficult to diagnose HIT because it can look like many other medical conditions and the best laboratory tests for HIT are difficult to run and only available at specialized centres.
It would be very helpful if doctors had tests they could use that would tell them quickly and accurately which patients with symptoms that look like HIT really do have HIT (and require urgent treatment with another type of blood thinner) and which patients are very unlikely to have HIT (and could continue to take heparin safely). In this study, the investigators will compare the 4T's score (a scoring system that assigns "points" to the presence or absence of specific clinical features) and a rapid laboratory test with the old laboratory test to find out if one or both of these types of tests are useful for telling doctors which patients have HIT and which patients don't have HIT.
|Heparin-Induced Thrombocytopenia||Device: ID-PaGIA Heparin/PF4 antibody test Procedure: Clinical Prediction Score-HIT Score Card||Phase 1|
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||Improving the Diagnosis of Heparin-Induced Thrombocytopenia: Utility of the 4T's Score and Evaluation of New Rapid Assays|
- Proportion of patients with a low or intermediate 4T's Score and a negative ID-PaGIA assay result who have a positive SRA. [ Time Frame: 30 days ]
|Study Start Date:||December 2007|
|Study Completion Date:||February 2013|
|Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
Device: ID-PaGIA Heparin/PF4 antibody test
- clinical prediction rule
- rapid immunoassay
Please refer to this study by its ClinicalTrials.gov identifier: NCT00489437
|Hamilton Health Sciences|
|Hamilton, Ontario, Canada, L8V 1C3|
|Principal Investigator:||Lori-Ann Linkins, MD, MSc||McMaster University|